CTLA-4: a moving target in immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works

B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes

Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058 · see citing works

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · see citing works

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511 · see citing works

T cell anergy

Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487 · see citing works

The CD28 Signaling Pathway Regulates Glucose Metabolism

Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475 · see citing works

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works

CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL

Boise, L., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210 · see citing works

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works

Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig

Kremer, J. M., Westhovens, R., Leon, M., Giorgio, E. D., Alten, R., Steinfeld, S. D., RUSSELL, A. S., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,053 · see citing works

T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds

Viola, A., & Lanzavecchia, A. (1996) · Science · doi:10.1126/science.273.5271.104 · Cited by 1,031 · see citing works

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · see citing works

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · see citing works

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

CD28 Costimulation: From Mechanism to Therapy

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · see citing works

B70 antigen is a second ligand for CTLA-4 and CD28

Azuma, M., Ito, D., Yagita∥, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 910 · see citing works

The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells

Martinez, G. J., Pereira, R. M., Äijö, T., Kim, E. Y., Marangoni, F., Pipkin, M. E., Togher, S., Heissmeyer, V., Zhang, Y. C., Crotty, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.006 · Cited by 857 · see citing works

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 854 · see citing works

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 836 · see citing works

Integrated molecular analysis of adult T cell leukemia/lymphoma

Kataoka, K., Nagata, Y., Kitanaka, A., Shiraishi, Y., Shimamura, T., Yasunaga, J., Totoki, Y., Chiba, K., Sato‐Otsubo, A., Nagae, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3415 · Cited by 819 · see citing works

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 786 · see citing works

Molecular Basis of T Cell Inactivation by CTLA-4

Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684 · see citing works

Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy

Lo, B., Zhang, K., Lü, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J. M., Marsh, R. A., et al. (2015) · Science · doi:10.1126/science.aaa1663 · Cited by 678 · see citing works

The Interaction Properties of Costimulatory Molecules Revisited

Collins, A. V., Brodie, D. W., Gilbert, R. J. C., Iaboni, A., Manso-Sancho, R., Walse, B., Stuart, D. I., van der Merwe, P. A., & Davis, S. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00362-x · Cited by 675 · see citing works

The Emerging Role of CTLA-4 as an Immune Attenuator

Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 633 · see citing works

CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2

Tai, X., Cowan, M. L., Feigenbaum, L., & Singer, A. (2005) · Nature Immunology · doi:10.1038/ni1160 · Cited by 613 · see citing works

Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR Engagement

Linsley, P. S., Bradshaw, J., Greene, J. L., Peach, R., Bennett, K. L., & Mittler, R. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80480-x · Cited by 608 · see citing works

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A. L., Alumkal, J. J., Scher, H. I., Chin, K. M., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 556 · see citing works

CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients

Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · see citing works

Why must T cells be cross-reactive?

Sewell, A. K. (2012) · Nature reviews. Immunology · doi:10.1038/nri3279 · Cited by 544 · see citing works

Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity

López‐Herrera, G., Tampella, G., Pan‐Hammarström, Q., Herholz, P., Trujillo-Vargas, C. M., Phadwal, K., Simon, A. K., Moutschen, M. P., Etzioni, A., Mory, A., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.015 · Cited by 519 · see citing works

B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center Formation

Borriello, F., Sethna, M. P., Boyd, S. D., Schweitzer, A. N., Tivol, E. A., Jacoby, D., Strom, T. B., Simpson, E. M., Freeman, G. J., & Sharpe, A. H. (1997) · Immunity · doi:10.1016/s1074-7613(00)80333-7 · Cited by 498 · see citing works

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492 · see citing works

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M., Seehra, J. S., Somers, W. S., & Mosyak, L. (2001) · Nature · doi:10.1038/35069118 · Cited by 487 · see citing works

Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch

Gubser, P. M., Bantug, G. R., Razik, L., Fischer, M., Dimeloe, S., Höenger, G., Müller-Durovic, B., Jauch, A., & Hess, C. (2013) · Nature Immunology · doi:10.1038/ni.2687 · Cited by 487 · see citing works

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460 · see citing works

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

Weber, J. S., Dummer, R., de Pril, V., Lebbé, C., Hodi, F. S., & for the MDX010‐20 Investigators (2013) · Cancer · doi:10.1002/cncr.27969 · Cited by 447 · see citing works

B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse

Pentcheva‐Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436 · see citing works

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Sanderson, K. M., Scotland, R., Lee, P. P., Liu, D., Groshen, S. G., Snively, J., Sian, S., Nichol, G. M., Davis, T. A., Keler, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 432 · see citing works

Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults

Su, L. F., Kidd, B. A., Han, A., Kotzin, J. J., & Davis, M. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.021 · Cited by 429 · see citing works

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T. N., Choi, E. M., Greenberg, N. M., Burg, M. B., & Allison, J. P. (2000) · PubMed · Cited by 425 · see citing works

Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family

Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391 · see citing works

Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383 · see citing works

Confusing signals: Recent progress in CTLA-4 biology

Walker, L. S. K., & Sansom, D. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.001 · Cited by 362 · see citing works

Duration of TCR Stimulation Determines Costimulatory Requirement of T Cells

Kündig, T. M., Shahinian, A., Kawai, K., Mittrücker, H., Sebzda, E., Bachmann, M. F., Mak, T. W., & Ohashi, P. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80308-8 · Cited by 356 · see citing works

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., Giacomo, A. M. D., Danielli, R., Altomonte, M., Mutti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70381-4 · Cited by 353 · see citing works

Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

Schwartz, J.-C. D., Zhang, X., Fedorov, A. A., Nathenson, S. G., & Almo, S. C. (2001) · Nature · doi:10.1038/35069112 · Cited by 350 · see citing works

Tyrosine Phosphorylation Controls Internalization of CTLA-4 by Regulating Its Interaction with Clathrin-Associated Adaptor Complex AP-2

Shiratori, T., Miyatake, S., Ohno, H., Nakaseko, C., Isono, K., Bonifacino, J. S., & Saito, T. (1997) · Immunity · doi:10.1016/s1074-7613(00)80346-5 · Cited by 345 · see citing works

The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation

DuPage, M., Chopra, G., Quiros, J., Rosenthal, W. L., Morar, M. M., Holohan, D., Zhang, R., Turka, L., Marson, A., & Bluestone, J. A. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.007 · Cited by 332 · see citing works

Environmental-Dependent Acceleration of a Developmental Switch: The Floral Transition

Simpson, G. G., & Dean, C. (2000) · Science s STKE · doi:10.1126/stke.2000.18.pe1 · Cited by 318 · see citing works

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

Camacho, L. H., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Gajewski, T. F., Redman, B. G., Pavlov, D., Bulanhagui, C. A., Bozon, V. A., Gómez-Navarro, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2435 · Cited by 309 · see citing works

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J. L., Villaseñor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 308 · see citing works

Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8+ T Lymphocytes

Yu, W., Jiang, N. J., Ebert, P. J. R., Kidd, B. A., Müller, S., Lund, P. J., Juang, J., Adachi, K., Tse, T., Birnbaum, M. E., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.001 · Cited by 301 · see citing works

Rac-dependent trans-endocytosis of ephrinBs regulates Eph–ephrin contact repulsion

Marston, D. J., Dickinson, S., & Nobes, C. D. (2003) · Nature Cell Biology · doi:10.1038/ncb1044 · Cited by 301 · see citing works

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D. K., Soulières, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301 · see citing works

The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency

Gámez-Díaz, L. Y., August, D., Stepensky, P., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.025 · Cited by 286 · see citing works

An Enigmatic Tail of CD28 Signaling

Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283 · see citing works

The self-obsession of T cells: how TCR signaling thresholds affect fate 'decisions' and effector function

Hogquist, K. A., & Jameson, S. C. (2014) · Nature Immunology · doi:10.1038/ni.2938 · Cited by 265 · see citing works

Impaired regulatory T cell function in germ‐free mice

Östman, S., Rask, C., Wold, A. E., Hultkrantz, S., & Telemo, E. (2006) · European Journal of Immunology · doi:10.1002/eji.200535244 · Cited by 257 · see citing works

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256 · see citing works

A cellular calculus for signal integration by T cells

Gett, A. V., & Hodgkin, P. D. (2000) · Nature Immunology · doi:10.1038/79782 · Cited by 246 · see citing works

Notch Ligand Endocytosis Generates Mechanical Pulling Force Dependent on Dynamin, Epsins, and Actin

Meloty-Kapella, L., Shergill, B. S., Kuon, J., Botvinick, E. L., & Weinmaster, G. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.04.005 · Cited by 239 · see citing works

CD4 + T Cell Tolerance to Tissue-Restricted Self Antigens Is Mediated by Antigen-Specific Regulatory T Cells Rather Than Deletion

Legoux, F. P., Lim, J., Cauley, A. W., Dikiy, S., Ertelt, J. M., Mariani, T. J., Sparwasser, T. D., Way, S. S., & Moon, J. J. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.011 · Cited by 238 · see citing works

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236 · see citing works

Cutting Edge: Lymphoproliferative Disease in the Absence of CTLA-4 Is Not T Cell Autonomous

Bachmann, M. F., Köhler, G., Ecabert, B., Mak, T. W., & Köpf, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1128 · Cited by 232 · see citing works

Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

Klocke, K., Sakaguchi, S., Holmdahl, R., & Wing, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603892113 · Cited by 232 · see citing works

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226 · see citing works

Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression

Chuang, E., Alegre, M., Duckett, C. S., Noel, P. J., Heiden, M. G. V., & Thompson, C. B. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.144 · Cited by 225 · see citing works

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J. S., Galbraith, S. M., Targan, S. R., & Wang, H. L. (2010) · PubMed Central · Cited by 225 · see citing works

Spatiotemporal Basis of CTLA-4 Costimulatory Molecule-Mediated Negative Regulation of T Cell Activation

Yokosuka, T., Kobayashi, W., Takamatsu, M., Sakata-Sogawa, K., Zeng, H., Hashimoto, A. S., Yagita∥, H., Tokunaga, M., & Saito, T. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.006 · Cited by 213 · see citing works

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

Paterson, A. M., Lovitch, S. B., Sage, P. T., Juneja, V. R., Lee, Y., Trombley, J. D., Arancibia-Cárcamo, C. V., Sobel, R. A., Rudensky, A. Y., Kuchroo, V. K., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141030 · Cited by 212 · see citing works

Studies Using Antigen-Presenting Cells Lacking Expression of Both B7-1 (CD80) and B7-2 (CD86) Show Distinct Requirements for B7 Molecules During Priming Versus Restimulation of Th2 But Not Th1 Cytokine Production

Schweitzer, A., & Sharpe, A. H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2762 · Cited by 211 · see citing works

An obligate cell-intrinsic function for CD28 in Tregs

Zhang, R., Huynh, A., Whitcher, G. H., Chang, J., Maltzman, J. S., & Turka, L. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65013 · Cited by 208 · see citing works

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Fazio, C., Annesi, D., Lenoci, M., Amato, G., Danielli, R., Altomonte, M., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00092-2 · Cited by 206 · see citing works

Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion

Marchingo, J. M., Kan, A., Sutherland, R. M., Duffy, K. R., Wellard, C. J., Belz, G. T., Lew, A. M., Dowling, M. R., Heinzel, S., & Hodgkin, P. D. (2014) · Science · doi:10.1126/science.1260044 · Cited by 202 · see citing works

Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals

Maeda, Y., Nishikawa, H., Sugiyama, D., Ha, D., Hamaguchi, M., Saito, T., Nishioka, M., Wing, J. B., Adeegbe, D. O., Katayama, I., et al. (2014) · Science · doi:10.1126/science.aaa1292 · Cited by 200 · see citing works

Tolerance is established in polyclonal CD4+ T cells by distinct mechanisms, according to self-peptide expression patterns

Malhotra, D., Linehan, J. L., Dileepan, T., Lee, Y. J., Purtha, W. E., Lu, J. V., Nelson, R. W., Fife, B. T., Orr, H. T., Anderson, M. S., et al. (2016) · Nature Immunology · doi:10.1038/ni.3327 · Cited by 194 · see citing works

The BEACH Is Hot: A LYST of Emerging Roles for BEACH ‐Domain Containing Proteins in Human Disease

Cullinane, A. R., Schäffer, A. A., & Huizing, M. (2013) · Traffic · doi:10.1111/tra.12069 · Cited by 186 · see citing works

Lymphoproliferative Disorder in CTLA-4 Knockout Mice Is Characterized by CD28-Regulated Activation of Th2 Responses

Khattri, R., Auger, J., Griffin, M. D., Sharpe, A. H., & Bluestone, J. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5784 · Cited by 181 · see citing works

Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein

Zhang, Y., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9273 · Cited by 181 · see citing works

CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement

Wang, C. J., Heuts, F. W. H., Ovcinnikovs, V., Wardzinski, L., Bowers, C., Schmidt, E. M., Kogimtzis, A., Kenefeck, R., Sansom, D. M., & Walker, L. S. K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414576112 · Cited by 179 · see citing works

Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation

Qureshi, O., Kaur, S., Hou, T. Z., Jeffery, L. E., Poulter, N. S., Briggs, Z., Kenefeck, R., Willox, A. K., Royle, S., Rappoport, J. Z., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304329 · Cited by 172 · see citing works

CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms

Ise, W., Kohyama, M., Nutsch, K., Lee, H. M., Suri, A., Unanue, E. R., Murphy, T. L., & MURPHY, K. M. M. (2009) · Nature Immunology · doi:10.1038/ni.1835 · Cited by 171 · see citing works

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., Wong, S. C., Bell, A., Mankikar, S., Rangan, V. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617941114 · Cited by 164 · see citing works

CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity

Schmidt, E. M., Wang, C. J., Ryan, G. A., Clough, L. E., Qureshi, O., Goodall, M. D., Abbas, A. K., Sharpe, A. H., Sansom, D. M., & Walker, L. S. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.274 · Cited by 155 · see citing works

A motif in the V3 domain of the kinase PKC-θ determines its localization in the immunological synapse and functions in T cells via association with CD28

Kong, K., Yokosuka, T., Canonigo-Balancio, A. J., Isakov, N., Saito, T., & Altman, A. (2011) · Nature Immunology · doi:10.1038/ni.2120 · Cited by 153 · see citing works

The reverse stop-signal model for CTLA4 function

Rudd, C. E. (2008) · Nature reviews. Immunology · doi:10.1038/nri2253 · Cited by 143 · see citing works

Abatacept for Crohn's Disease and Ulcerative Colitis

Sandborn, W. J., Colombel, J., Sands, B. E., Rutgeerts, P. J., Targan, S. R., Panaccione, R., Bressler, B. L., Geboes, K., Schreiber, S., Aranda, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.010 · Cited by 142 · see citing works

Protein kinase C-η controls CTLA-4–mediated regulatory T cell function

Kong, K., Fu, G., Zhang, Y., Yokosuka, T., Casas, J., Canonigo-Balancio, A. J., Bécart, S., Kim, G., Yates, J. R., Kronenberg, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2866 · Cited by 136 · see citing works

Recurrent activating mutations of CD28 in peripheral T-cell lymphomas

Rohr, J. M., Guo, S., Huo, J., Bouska, A. C., Lachel, C. M., Li, Y., Simone, P. D., Zhang, W., Gong, Q., Wang, C., et al. (2015) · Leukemia · doi:10.1038/leu.2015.357 · Cited by 134 · see citing works

Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4

Lee, S., Moon, J. S., Lee, C., Kim, H., Baek, S.-M., Hwang, S., Kang, G. H., Seo, J. K., Shin, C. H., Kang, H. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.036 · Cited by 133 · see citing works

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

Ribas, A., Comı́n-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132 · see citing works

Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti–CTLA-4 antibodies

Lute, K. D., May, K. F., Lu, P., Zhang, H., Kocak, E., Mosinger, B., Wolford, C. C., Phillips, G. S., Caligiuri, M. A., Zheng, P., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2298 · Cited by 117 · see citing works

A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells

Hou, T. Z., Qureshi, O., Wang, C. J., Baker, J., Young, S. P., Walker, L. S. K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401876 · Cited by 115 · see citing works

B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro

Sansom, D. M., & Hall, N. D. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230148 · Cited by 110 · see citing works

The lymphoid lineage–specific actin-uncapping protein Rltpr is essential for costimulation via CD28 and the development of regulatory T cells

Liang, Y., Cucchetti, M., Roncagalli, R., Yokosuka, T., Malzac, A., Bertosio, E., Imbert, J., Nijman, I. J., Suchánek, M., Saito, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2634 · Cited by 106 · see citing works

CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

Menard, C., Ghiringhelli, F., Roux, S., Chaput, N., Mateus, C., Grohmann, U., Caillat‐Zucman, S., Zitvogel, L., & Robert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4797 · Cited by 106 · see citing works

Degradation of connexins and gap junctions

Falk, M. M., Kells, R. M., & Berthoud, V. M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.01.031 · Cited by 104 · see citing works

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations

Hou, T. Z., Verma, N., Wanders, J., Kennedy, A., Soskic, B., Janman, D., Halliday, N., Rowshanravan, B., Worth, A. J. J., Qasim, W., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745174 · Cited by 104 · see citing works

Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling

Tan, Y. X., Manz, B. N., Freedman, T. S., Zhang, C., Shokat, K. M., & Weiss, A. (2013) · Nature Immunology · doi:10.1038/ni.2772 · Cited by 101 · see citing works

CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response

Martínez‐Llordella, M., Esensten, J. H., Bailey-Bucktrout, S. L., Lipsky, R. H., Marini, A. M., Chen, J., Mughal, M. R., Mattson, M. P., Taub, D. D., & Bluestone, J. A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122387 · Cited by 100 · see citing works

Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08

Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97 · see citing works

Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans

Corse, E., & Allison, J. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200695 · Cited by 97 · see citing works

Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases

Kitchlu, A., Fingrut, W. B., Ávila-Casado, C., Chan, C. T., Crump, M., Hogg, D., & Reich, H. N. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.04.026 · Cited by 90 · see citing works

Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells

Wang, C. J., Kenefeck, R., Wardzinski, L., Attridge, K., Manzotti, C. N., Schmidt, E. M., Qureshi, O., Sansom, D. M., & Walker, L. S. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200972 · Cited by 85 · see citing works

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Comı́n-Anduix, B., Lee, Y., Jalil, J., Algazi, A. P., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-22 · Cited by 82 · see citing works

Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor

Tian, R., Wang, H., Gish, G. D., Petsalaki, E., Pasculescu, A., Shi, Y., Mollenauer, M. N., Bagshaw, R. D., Yosef, N., Hunter, T. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503286112 · Cited by 76 · see citing works

Costimulatory Receptors in a Teleost Fish: Typical CD28, Elusive CTLA4

Bernard, D., Riteau, B., Hansen, J. D., Phillips, R. B., Michel, F., Boudinot, P., & Benmansour, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.4191 · Cited by 75 · see citing works

Efficient Culture of Human Naive and Memory B Cells for Use as APCs

Su, K., Watanabe, A., Yeh, C., Kelsoe, G. H., & Kuraoka, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502193 · Cited by 75 · see citing works

Cell‐intrinsic and ‐extrinsic control of T reg‐cell homeostasis and function revealed by induced CD 28 deletion

Gogishvili, T., Lühder, F., Goebbels, S., Beer‐Hammer, S., Pfeffer, K., & Hünig, T. (2012) · European Journal of Immunology · doi:10.1002/eji.201242824 · Cited by 57 · see citing works

Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation

Sun, T., Hu, Z., Shen, H., & Lin, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0176 · Cited by 56 · see citing works

The rise and fall of the <scp>CD</scp> 28 superagonist <scp>TGN</scp> 1412 and its return as <scp>TAB</scp> 08: a personal account

Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47 · see citing works

A Transendocytosis Perspective on the CD28/CTLA-4 Pathway

Soskic, B., Qureshi, O. S., Hou, T., & Sansom, D. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00004-2 · Cited by 41 · see citing works

CD28 and ITK signals regulate autoreactive T cell trafficking

Jain, N., Miu, B., Jiang, J., McKinstry, K. K., Prince, A., Swain, S. L., Greiner, D. L., Thomas, C. J., Sanderson, M. J., Berg, L. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3393 · Cited by 39 · see citing works

Trans-endocytosis of CD47 and SHPS-1 and its role in regulation of the CD47–SHPS-1 system

Kusakari, S., Ohnishi, H., Jin, F.-J., Kaneko, Y., Murata, T., Murata, Y., Okazawa, H., & Matozaki, T. (2008) · Journal of Cell Science · doi:10.1242/jcs.025015 · Cited by 33 · see citing works

Rab8 Binding to Immune Cell-Specific Adaptor LAX Facilitates Formation of trans -Golgi Network-Proximal CTLA-4 Vesicles for Surface Expression

Banton, M. C., Inder, K. L., Valk, E., Rudd, C. E., & Schneider, H. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01331-13 · Cited by 33 · see citing works

RIPping Notch Apart: A New Role for Endocytosis in Signal Transduction?

Krämer, H. (2000) · Science s STKE · doi:10.1126/stke.2000.29.pe1 · Cited by 26 · see citing works

1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept

Gardner, D. H., Jeffery, L. E., Soskic, B., Briggs, Z., Hou, T. Z., Raza, K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500306 · Cited by 23 · see citing works

Inducible Deletion of CD28 Prior to Secondary Nippostrongylus brasiliensis Infection Impairs Worm Expulsion and Recall of Protective Memory CD4+ T Cell Responses

Ndlovu, H., Darby, M., Froelich, M., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003906 · Cited by 21 · see citing works

Interrupting CD28 costimulation before antigen rechallenge affects CD8+ T‐cell expansion and effector functions during secondary response in mice

Fröhlich, M., Gogishvili, T., Langenhorst, D., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546232 · Cited by 21 · see citing works

Comparison of the Intracellular Trafficking Itinerary of CTLA-4 Orthologues

Kaur, S., Qureshi, O., & Sansom, D. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060903 · Cited by 16 · see citing works

Inter-Cellular Exchange of Cellular Components via VE-Cadherin-Dependent Trans-Endocytosis

Sakurai, T., Woolls, M. J., Jin, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090736 · Cited by 10 · see citing works

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · see citing works

Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576 · see citing works

Cell-cell communication: New insights and clinical implications

Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433 · see citing works

Colorectal liver metastasis: molecular mechanism and interventional therapy

Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298 · see citing works

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179 · see citing works

The promising immune checkpoint LAG‐3 in cancer immunotherapy: from basic research to clinical application

Huo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176 · see citing works

Prospects for combining immune checkpoint blockade with PARP inhibition

Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143 · see citing works

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136 · see citing works

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology &amp; Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96 · see citing works

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66 · see citing works

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65 · see citing works

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works

The regulation of immune checkpoints by the hypoxic tumor microenvironment

Hu, M., Li, Y., Lu, Y., Wang, M., Li, Y., Wang, C., Li, Q., & Zhao, H. (2021) · PeerJ · doi:10.7717/peerj.11306 · Cited by 51 · see citing works

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology &amp; Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40 · see citing works

Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword

Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works

Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm

Panoskaltsis, N., McCarthy, N. E., Stagg, A. J., Mummery, C. J., Husni, M., Arebi, N., Greenstein, D., Price, C. L., Al-Hassi, H. O., Koutinas, M., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02725-2 · Cited by 16 · see citing works

Shared genetic architecture between hypothyroidism and rheumatoid arthritis: a large-scale cross-trait analysis.

Liu, R., Shang, X., Fu, Y., Wang, Y., Wang, P., & Yan, S. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.02.002 · Cited by 13 · see citing works

Research progress on immunotherapeutics for triple-negative breast cancer from a single-cell perspective

Yuan, Z., Liu, Z., Zhou, M., Wen, H., & Li, B. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105111 · Cited by 6 · see citing works

Expression of TIGIT, BTLA, LAG3, FCRL3 and CTLA-4 in Sézary Syndrome

Anzengruber, F., Ignatova, D., Eberle-Schläpfer, T., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.153

Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome

Anzengruber, F., Ignatova, D., Schlaepfer, T., Chang, Y., French, L. E., Pascolo, S., Contassot, E., Bobrowicz, M., Hoetzenecker, W., & Guenova, E. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1564827 · Cited by 31 · see citing works

Tumor cell-intrinsic expression of BTLA, ICOS and TIGIT in human breast cancer.Preprint

Mamoor, S. (2023) · doi:10.31219/osf.io/xhz3g

A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer

Li, X., Wang, R., Fan, P., Yao, X., Qin, L., Peng, Y., Ma, M., Asley, N., Chang, X., Feng, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01066 · Cited by 66 · see citing works

Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients

Al-Mterin, M. A., Alsalman, A., & Elkord, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870283 · Cited by 34 · see citing works